Looking at affordability and patient-recorded outcomes, the panel will address the future of immuno-X therapies, therapy experiences and drug interactions, as well as patient-centric dosage forms and medical devices, with a focus on patient centricity driven and enabled by end users: patients and healthcare providers in an R&D partnership. Examining the “Voice of the Patient,” patient representation at the technology assessment stage and validating outcome measures, the panel will discuss how to improve compliance, patient-physician commitment and product-derived value.